Morphosys AG - ADR

MorphoSys AG operates as a commercial-stage biopharmaceutical company. It uses groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. The firm also engages in the development and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Incyte

The European Commission (EC) has granted conditional approval to Incyte Corporation (NASDAQ: INCY) - MorphoSys AG's (NASDAQ: MOR) Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval covers Minjuvi combined with lenalidomide, followed by Minjuvi monotherapy, for DLBCL patients who are not eligible for autologous stem cell transplant (ASCT).

Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval

-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Union (EU), addressing an urgent unmet medical need - In Europe, each year approximately 16,000 patients are diagnosed with relapsed or refractory DLBCL1,2,3 PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / August 26, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) and Incyte (INCY) today announced that the European Commission (EC) has granted conditional marketing authorization for Minjuvi® (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). The EC Decision follows the positive opinion received from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in June 2021 recommending the conditional marketing authorization of Minjuvi.

MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 17, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announced today that Incyte, its development and commercialization partner for tafasitamab, entered into a collaboration and license agreement with a subsidiary of InnoCare for tafasitamab in Greater China. Under the terms of the agreement, InnoCare will receive the rights to develop and exclusively commercialize tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in hematology-oncology in mainland China, Hong Kong, Macau and Taiwan.

MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2021 Results - Earnings Call Transcript

- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q - MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals - Announced and closed ~US$ 2.0 billion strategic funding partnership with Royalty Pharma - Updated group financial guidance - Conference call and webcast (in English) tomorrow, July 29, 2021, at 2:00pm CEST (1:00pm BST/8:00am EDT) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 29, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) reports financial results for the second quarter and the first half year of 2021. "We regained the momentum in Monjuvi sales as we exited the second quarter and are encouraged to see that momentum continuing into Q3," said Jean-Paul Kress, M.D.

MorphoSys AG Reports Second Quarter and First Half 2021 Results

MorphoSys AG (NASDAQ: MOR) expects group revenues of €155 million to €180 million (previously: €150 to € 200 million, provided on March 15 and reiterated on May 5, 2021).  The updated revenue guidance primarily reflects updated Monjuvi product sales expectations.

MorphoSys Stock Falls After Trimming Upper End Of 2021 Revenue Outlook

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announces today an update of its financial guidance for 2021 after preliminary completion of the latest evaluation of MorphoSys' half year 2021 financial performance.

MorphoSys AG to Update Financial Guidance for 2021 and Reduce Financial Liabilities

PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT). MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.

Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021

PLANEGG, GERMANY / ACCESSWIRE / July 16, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a resolution to increase the share capital of MorphoSys AG by issuing 1,337,552 new ordinary shares from the Authorized Capital 2021-II, excluding pre-emptive rights of existing shareholders, to implement the purchase of 1,337,552 new ordinary shares by Royalty Pharma Investments 2019 ICAV, a subsidiary of Royalty Pharma plc (NASDAQ: RPRX) ("Royalty Pharma"). The new ordinary shares represent 3.9% of the registered share capital of MorphoSys following the capital increase.

MorphoSys Concludes a US $100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma

Constellation Pharmaceuticals Inc

Company Announces Successful Completion of Tender Offer   Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") for $34.00 per share, net to the seller in cash, without interest and subject to any applicable withholding of taxes. The tender offer expired at one minute after 11:59 p.m.

MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology

MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) ("Constellation"). The expiration of the HSR waiting period satisfies one of the conditions to the tender offer, which is scheduled to expire at one minute past 11:59 p.m.

MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals

If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union The positive opinion from the CHMP is based on data from the Phase 2 L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / June 25, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional marketing authorization of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT). "The CHMP's positive opinion of tafasitamab is a pivotal step towards addressing an urgent unmet medical need for the 30-40% of patients with relapsed or refractory DLBCL who do not respond to initial therapy or relapse thereafter," said Steven Stein, M.D.

MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constellation Pharmaceuticals, Inc., (CNST) ("Constellation") for $34.00 per share, net to the seller in cash, without interest, and subject to any applicable withholding of taxes. The tender offer is being made pursuant to the previously announced merger agreement, dated June 2, 2021 between MorphoSys and Constellation.

MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR) (NASDAQ:MOR), and Incyte (NASDAQ:INCY) today announced new three-year follow-up data from the ongoing Phase 2 L-MIND study of tafasitamab (Monjuvi(R)) in combination with lenalidomide in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A total of 80 out of 81 enrolled study patients receiving tafasitamab plus lenalidomide were included in the efficacy analysis at approximately three years follow-up (>=35 months).

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

Investors weren't happy about the drugmaker's wheeling and dealing.

Why MorphoSys Stock Sank This Week

Constellation (CNST) skyrockets following the acquisition deal with German biotech company, MorphoSys, worth $1.7 billion.

Constellation (CNST) Surges on Takeover Deal With MorphoSys

NEW YORK, June 2, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Constellation Pharmaceuticals, Inc. ("Constellation" or the "Company") (NASDAQ: CNST) in connection with the proposed acquisition of the Company by MorphoSys AG ("MorphoSys") (FSE: MOR; NASDAQ: MOR). The transaction is structured as an all-cash tender offer pursuant to which the Company's shareholders will receive $34.00 for each share of Constellation common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Constellation Pharmaceuticals, Inc.

Royalty Pharma

MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of $1.7 billion. The transaction is expected to close in the third quarter of 2021.

MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma

Shares of MorphoSys AG ADR were down 8.9% in premarket trading on Wednesday after the company announced a $1.7 billion acquisition of Constellation Pharmaceuticals Inc. . Constellation's stock soared 61.3% in premarket trade.

MorphoSys to buy Constellation Pharma for $1.7 billion; Constellation's stock soars 61%

MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) ("Constellation") whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the Management Board (Vorstand) and the Supervisory Board (Aufsichtsrat) of MorphoSys, as well as the Board of Directors of Constellation and is expected to close in the third quarter of 2021.

MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma

PLANEGG/MUNICH, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”), and Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) (“Constellation”) today announced that they have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the management board (Vorstand) and the supervisory board (Aufsich

MorphoSys to Acquire Constellation Pharmaceuticals

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday May 25, 2021 at 7:00 a.m.

MorphoSys To Participate in UBS Global Healthcare Conference

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 19, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi(R)) development program will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021. Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, which was approved as Monjuvi(R) (tafasitamab-cxix) in July 2020 by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma (DLBCL). Tafasitamab is a humanized, monoclonal antibody designed to effectively target the B-cell specific antigen CD19 and to induce immune cell activation.

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q1 2021 Results - Earnings Call Transcript

News for Morphosys AG - ADR Stock (MOR)